» Articles » PMID: 39366930

Regulation of HNRNP Family by Post-translational Modifications in Cancer

Overview
Date 2024 Oct 4
PMID 39366930
Authors
Affiliations
Soon will be listed here.
Abstract

Heterogeneous nuclear ribonucleoproteins (HNRNPs) represent a large family of RNA-binding proteins consisting of more than 20 members and have attracted great attention with their distinctive roles in cancer progression by regulating RNA splicing, transcription, and translation. Nevertheless, the cancer-specific modulation of HNRNPs has not been fully elucidated. The research of LC-MS/MS technology has documented that HNRNPs were widely and significantly targeted by different post-translational modifications (PTMs), which have emerged as core regulators in shaping protein functions and are involved in multiple physiological processes. Accumulating studies have highlighted that several PTMs are involved in the mechanisms of HNRNPs regulation in cancer and may be suitable therapeutic targets. In this review, we summarize the existing evidence describing how PTMs modulate HNRNPs functions on gene regulation and the involvement of their dysregulation in cancer, which will help shed insights on their clinical impacts as well as possible therapeutic tools targeting PTMs on HNRNPs.

Citing Articles

Alternative Splicing at the Crossroad of Inflammatory Bowel Diseases and Colitis-Associated Colon Cancer.

Matos P, Jordan P Cancers (Basel). 2025; 17(2).

PMID: 39858001 PMC: 11764256. DOI: 10.3390/cancers17020219.

References
1.
Britton S, Froment C, Frit P, Monsarrat B, Salles B, Calsou P . Cell nonhomologous end joining capacity controls SAF-A phosphorylation by DNA-PK in response to DNA double-strand breaks inducers. Cell Cycle. 2009; 8(22):3717-22. DOI: 10.4161/cc.8.22.10025. View

2.
Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

3.
Beyer A, Christensen M, Walker B, Lestourgeon W . Identification and characterization of the packaging proteins of core 40S hnRNP particles. Cell. 1977; 11(1):127-38. DOI: 10.1016/0092-8674(77)90323-3. View

4.
Antonello Z, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P . Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF. Oncotarget. 2017; 8(49):84743-84760. PMC: 5689570. DOI: 10.18632/oncotarget.21262. View

5.
Diao X, Guo C, Zheng H, Zhao K, Luo Y, An M . SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer. Signal Transduct Target Ther. 2023; 8(1):426. PMC: 10625632. DOI: 10.1038/s41392-023-01685-0. View